Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 3;12(16):6931-6954.
doi: 10.7150/thno.77949. eCollection 2022.

Artificial intelligence in pancreatic cancer

Affiliations
Review

Artificial intelligence in pancreatic cancer

Bowen Huang et al. Theranostics. .

Abstract

Pancreatic cancer is the deadliest disease, with a five-year overall survival rate of just 11%. The pancreatic cancer patients diagnosed with early screening have a median overall survival of nearly ten years, compared with 1.5 years for those not diagnosed with early screening. Therefore, early diagnosis and early treatment of pancreatic cancer are particularly critical. However, as a rare disease, the general screening cost of pancreatic cancer is high, the accuracy of existing tumor markers is not enough, and the efficacy of treatment methods is not exact. In terms of early diagnosis, artificial intelligence technology can quickly locate high-risk groups through medical images, pathological examination, biomarkers, and other aspects, then screening pancreatic cancer lesions early. At the same time, the artificial intelligence algorithm can also be used to predict the survival time, recurrence risk, metastasis, and therapy response which could affect the prognosis. In addition, artificial intelligence is widely used in pancreatic cancer health records, estimating medical imaging parameters, developing computer-aided diagnosis systems, etc. Advances in AI applications for pancreatic cancer will require a concerted effort among clinicians, basic scientists, statisticians, and engineers. Although it has some limitations, it will play an essential role in overcoming pancreatic cancer in the foreseeable future due to its mighty computing power.

Keywords: Artificial intelligence; early detection; machine learning; pancreatic cancer; prognosis prediction.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
The relationship between artificial intelligence, machine learning, and deep learning. Artificial intelligence refers to the use of machines to simulate human intelligence. Machine learning is a subfield of artificial intelligence, which mainly studies how to simulate or realize the learning function in human intelligence. The deep learning model is a subset of machine learning, which is a model combining multi-layer neural networks.
Figure 2
Figure 2
Based on labels, machine learning can be classified as supervised (A), unsupervised (B), semi-supervised (C), reinforcement learning (D), and ensemble learning (E) that integrates multiple algorithms. In supervised learning, all data is labeled, while unsupervised learning is unlabeled. Semi-supervised learning contains a small amount of labeled data and a large amount of unlabeled data. Reinforcement learning is when the agent interacts with the unknown environment and obtains rewards or punishments from the environment. In ensemble learning, multiple algorithms are integrated to solve problems. The algorithms may be parallel (Bagging) or sequential (Boosting).
Figure 3
Figure 3
Schematic diagram of machine learning and deep learning process. Traditional machine learning usually needs four steps: input, feature extraction, classification, and output. Moreover, deep learning is a subset of a machine learning algorithm, which can extract labels by itself without manual extraction.
Figure 4
Figure 4
Application of artificial intelligence in multiple related fields of pancreatic cancer. Artificial intelligence can use one type of data alone to make predictions about pancreatic cancer or integrate multi-omics information for analysis.

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: A Cancer Journal for Clinicians. 2022;72:7–33. - PubMed
    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71:209–49. - PubMed
    1. Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R. et al. Cancer incidence and mortality in China, 2016. Journal of the National Cancer Center. 2022;2:1–9. - PMC - PubMed
    1. Walter FM, Mills K, Mendonça SC, Abel GA, Basu B, Carroll N. et al. Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study. Lancet Gastroenterol Hepatol. 2016;1:298–306. - PMC - PubMed
    1. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y. et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. New Engl J Med. 2011;364:1817–25. - PubMed

Publication types

Substances